Norris Financial Group LLC Takes $2.51 Million Position in Pfizer Inc. $PFE

Norris Financial Group LLC bought a new position in Pfizer Inc. (NYSE:PFE) during the first quarter, HoldingsChannel reports. The firm bought 89,229 shares of the biopharmaceutical company’s stock, valued at approximately $2,506,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Evolution Wealth Management Inc. increased its position in shares of Pfizer by 132.2% during the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 566 shares in the last quarter. Godfrey Financial Associates Inc. bought a new stake in Pfizer during the 4th quarter worth approximately $26,000. YANKCOM Partnership purchased a new stake in shares of Pfizer in the fourth quarter worth approximately $28,000. HFM Investment Advisors LLC lifted its holdings in shares of Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 427 shares in the last quarter. Finally, Global Trust Asset Management LLC boosted its position in shares of Pfizer by 126.7% during the first quarter. Global Trust Asset Management LLC now owns 1,163 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 650 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on PFE shares. JPMorgan Chase & Co. reduced their price objective on Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a research note on Wednesday, July 8th. Morgan Stanley boosted their price target on shares of Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a report on Friday, April 10th. Guggenheim reduced their price target on shares of Pfizer from $36.00 to $35.00 and set a “buy” rating for the company in a research report on Monday, July 13th. UBS Group reaffirmed a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a research report on Wednesday, May 27th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $27.00 target price on shares of Pfizer in a research note on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $28.50.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Encouraging vitiligo data could strengthen Pfizer’s growth pipeline. Two Phase 3 trials showed that LITFULO significantly improved skin repigmentation in patients with nonsegmental vitiligo. Pfizer plans global regulatory submissions, potentially expanding the drug beyond its existing uses and creating a new commercial opportunity. Pfizer’s oral drug restores skin pigmentation in late-stage vitiligo trials
• Positive Sentiment: EU authorization for the updated COVID-19 vaccine supports the 2026–2027 season. The European Commission approved Pfizer and BioNTech’s XFG-adapted Comirnaty vaccine for people six months and older across the European Union. The decision allows manufacturing and supply preparations, although the mature and seasonal COVID market may limit the financial upside. Pfizer Wins EU Approval For Updated COVID Vaccine Ahead Of 2026 Season
• Positive Sentiment: Pfizer continues to build its oncology pipeline. The company is advancing the Phase 2 Symbiotic-Lung-10 trial, offering potential long-term upside if the lung-cancer program produces favorable results. However, Phase 2 development means any revenue contribution remains several years away. Pfizer’s Symbiotic-Lung-10 Trial
• Neutral Sentiment: Investors are focused on the upcoming second-quarter report. Preview reports highlight expectations for key products, COVID-related headwinds, and possible updates to full-year guidance. Pfizer’s latest quarter exceeded estimates, but earnings declined year over year, leaving results and management commentary as the near-term catalysts. Pfizer Q2 Earnings Preview
• Positive Sentiment: Additional vaccine demand may support established products. Québec selected Pfizer’s Prevnar 20 for its publicly funded pediatric pneumococcal immunization program, providing a potential boost to vaccine sales and market presence. Pfizer’s PREVNAR 20 Selected for Québec Program

Pfizer Stock Down 0.9%

Shares of NYSE PFE opened at $24.92 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The stock has a market capitalization of $142.04 billion, a PE ratio of 19.02 and a beta of 0.35. Pfizer Inc. has a one year low of $23.11 and a one year high of $28.75. The business’s fifty day moving average price is $25.06 and its 200-day moving average price is $26.16.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The business had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities research analysts anticipate that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 6.9%. Pfizer’s dividend payout ratio (DPR) is 131.30%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.